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Abstract
Background: Hypoxic tumor cells can reduce the efficacy of radiation. Antiangiogenic therapy may transiently ‘‘normalize’’
the tumor vasculature to make it more efficient for oxygen delivery. The aim of this study is to investigate whether the
recombinant human endostatin (endostar) can create a ‘‘vascular normalization window’’ to alleviate hypoxia and enhance
the inhibitory effects of radiation therapy in human nasopharyngeal carcinoma (NPC) in mice.
Methodology/Principal Findings: Transient changes in morphology of tumor vasculature and hypoxic tumor cell fraction in
response to endostar were detected in mice bearing CNE-2 and 5–8F human NPC xenografts. Various treatment schedules
were tested to assess the influence of endostar on the effect of radiation therapy. Several important factors relevant to the
angiogenesis were identified through immunohistochemical staining. During endostar treatment, tumor vascularity
decreased, while the basement membrane and pericyte coverage associated with endothelial cells increased, which
supported the idea of vessel normalization. Hypoxic tumor cell fraction also decreased after the treatment. The transient
modulation of tumor physiology caused by endostar improved the effect of radiation treatment compared with other
treatment schedules. The expressions of vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2),
MMP-9, and MMP-14 decreased, while the level of pigment epithelium-derived factor (PEDF) increased.
Conclusions: Endostar normalized tumor vasculature, which alleviated hypoxia and significantly sensitized the function of
radiation in anti-tumor in human NPC. The results provide an important experimental basis for combining endostar with
radiation therapy in human NPC.
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Introduction
The survival, growth, and metastasis of solid tumors are
dependent on tumor blood vessels [1,2]. Tumor vessels are both
structurally and functionally abnormal compared with normal
vessels, bearing defective endothelium, basement membrane and
pericyte coverage. Blood vessels are immature, tortuous, dilated,
and saccular, and have a haphazard pattern of interconnection.
These structural abnormalities contribute to spatial and temporal
heterogeneity in tumor blood flow, thus impairing the delivery of
oxygen [2,3,4].
Hypoxia is a common phenomenon in solid tumors and is
associated with aggressive clinical phenotype and poor prognosis
[5,6]. Resistance of hypoxic tumor cells to radiation is a significant
reason of failure in the local control of tumors, especially the
squamous cell carcinomas. Over 50 years ago Thomlinson and
Gray discovered the resistance of hypoxic cells to radiation
therapy, since then researchers have been attempting to eliminate
tumor hypoxia, but there is no effective approach [7].
Since one of the major factors causing hypoxia is the inadequate
vascular supply of tumor, more recent attempts to improve tumor
radiation response have involved specifically targeting the tumor
blood supply. However, this strategy also seems counterintuitive: it
is a widely held belief that antiangiogenic therapy eradicates tumor
vasculature, thus depriving the tumor of oxygen and nutrients.
However, preclinical models have shown that antiangiogenic
therapy may transiently ‘‘normalize’’ the tumor vasculature to
make it more efficient for oxygen delivery, thereby providing a
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treatment [3,8,9,10,11,12,13,14,15,16]. Since there are no guide-
lines for optimal scheduling of antiangiogenic therapy and
radiation therapy, the timing of the administration of antiangio-
genic agents, relative to the delivery of ionizing radiation, would
be critical for optimizing the antitumor effect of these treatments.
Nasopharyngeal carcinoma (NPC) is fairly rare among Cauca-
sians in Western Europe and North America, but there is a higher
incidence in Southeast Asia. NPC is sensitive to radiotherapy.
Radiotherapy or combined chemoradiation therapy is the
mainstay treatment modality. Now distant metastasis remains a
major cause of death [17]. Advances in radiation and chemother-
apy have also improved the prognosis of individuals with NPC.
However, patients still may suffer from the disease as a result of
local-regional therapeutic resistance, which results from tumor
hypoxia in NPC. It therefore makes sense to improve treatment
efficacy for patients with NPC [18]. Recently, tumor vascular
normalization was found in several solid tumors, but such role of
antiangiogenic agents in NPC remains unknown.
Endostatin, a 20 kD C-terminal fragment of collagen XVIII, is
an endogenous inhibitor of angiogenesis [19]. Endostar, tradition-
al endostatin with an additional nine-amino acid sequence at the
N-terminal of the protein and a six-histidine tag, were reported to
be more efficient in blocking angiogenesis and suppressing primary
tumor and metastasis growth [20]. Endostar was approved by the
State Food and Drug Administration (SFDA) for the treatment of
non-small cell lung cancer (NSCLC) in 2005. Phase III and IV
clinical studies have verified that combining endostar with
standard chemotherapy regimens could successfully improve the
median survival time and overall survival rate of patients with
advanced NSCLC [21]. However, the effects of endostar
combined with radiotherapy have been unclear.
We hypothesized that endostar could normalize the morphology
and function of NPC vasculature for a period of time, leading to
transient improvement in tumor oxygenation and response to
radiation therapy. Here, we investigated transient changes in
morphology of tumor vasculature and hypoxic tumor fraction in
response to endostar in human NPC in mice. We evaluated the
effects of endostar combined with radiation therapy in human
NPC and also explored potential mechanisms.
Materials and Methods
Ethics statement
All animal work was conducted according to relevant national
and international guidelines. The animal use protocol has been
reviewed and approved by the institutional animal care and use
committee of Sun Yat-Sen University (IACUC SYSU,
NO.20100703004). For details please refer to subsection entitled
Cell culture and animal model.
Cell culture and animal model
Male BALB/c nude mice, aged 5–6 weeks, were purchased
from the Shanghai Laboratory Animal Center of Chinese
Academy of Sciences (Shanghai, China). Mice were allowed to
acclimate to local conditions for at least 1 week and maintained
under a 12-hours dark, 12-hours light cycle with food and water ad
libitum. All of the experiments were carried out in accordance with
guidelines approved by the Laboratory Animal Center of Sun Yat-
sen University. Two poorly differentiated nasopharyngeal carci-
noma cell lines (CNE-2 and 5–8F) [22,23] (conserved in our
laboratory) were maintained in RPMI 1640 medium supplement-
ed with 10% fetal bovine serum, 100 units/ml penicillin G, and
100 ng/ml streptomycin at 37uCi n5 %C O 2 [24,25]. Cells were
diluted to a concentration of 10
7/mL in phosphate buffer solution
(PBS); mice were injected subcutaneously with 0.1 ml of the
suspension into the right back flank.
Radiation delivery
Local irradiation of the implanted tumor was administered
using a customized mouse jig with other parts of the body shielded
with lead. Each mouse was confined to a customized mouse jig
with a circular window, through which the tumor bed was exposed
to the radiation and irradiated locally. Mice were exposed to X-
rays with 5-mm thick lead shields when the tumor bed was gently
extended into the radiation field. Tumors were locally irradiated
with 6 Gy of 160 kV X-rays using RS 2000 X-ray Biological
Irradiator (Rad Source Technologies, USA) at a dose rate of 1Gy/
min through a 0.2-mm copper filter.
Treatments
The treatments were initiated when tumors reached a size of
about 100 mm
3. Control animals were injected with 0.9% saline
only. For the treated groups, endostar (20 mg/kg/d) diluted in
0.9% saline was administered subcutaneously. Endostar was
provided by Simcere Pharmaceutical Research Co., Ltd. When
the treatment modalities were combined, mice bearing CNE-2
tumor were randomly assigned to six treatment groups (n=6–8
per group): untreated control, endostar alone (20 mg/kg/d for 10
days from the first day of treatment), radiation alone (6 Gy), and
radiation in combination with endostar (20 mg/kg/d for 10 days
from the first day of treatment), which radiotherapy was delivered
at day 3, day 5, or day 9 after the first endostar injection. Again,
mice bearing 5–8 tumors were randomly assigned to five treatment
groups as we combined the treatment modalities (n=6–8 per
group): untreated control, endostar alone (20 mg/kg/d for 10 days
from the first day of treatment), radiation alone (6 Gy), and
radiation in combination with endostar (20 mg/kg/d for 10 days
from the first day of treatment), which radiotherapy was delivered
at 3 or 7 days after the first endostar injection. Tumor volume was
measured by using a caliper every other day and calculated
according to the following formula: V=L6W
2/2 (L, length; W,
width). Body weights of mice were monitored as an indirect
measurement of general toxicity.
Whole-mount staining for tumor vascularity
Primary tumors were double stained using a whole-mount
staining protocol for CD31 and type IV collagen/NG2 [26,27]
(n=4–6 animals per group). Sections of tissues were fixed in 4%
formalin overnight, cut at a thickness of 60 mm. Sections dried on
superfrost plus slides were permeabilized with PBS containing
0.3% triton X-100, and treated with proteinase K (20 mg/ml).
Specimens were incubated for 1 hour in a blocking solution
containing 4% goat serum, and then incubated with primary
antibodies at 4uC over night. Endothelial cells, vascular basement
membrane, and pericytes of tumor vessels were identified by
staining with combinations of two antibodies. Endothelial cells
were labeled with rat monoclonal anti-CD31 (PECAM-1, clone
MEC 13.3; 1:500; Biosciences-Pharmingen). Vascular basement
membrane was examined with rabbit polyclonal anti-type IV
collagen antibody (1:2,000; Chemicon). Pericytes were labeled
with rabbit anti-mouse NG2 antibody (1:400; Chemicon). Tumor
tissues were double-stained with an anti-CD31 antibody and an
anti-type IV collagen or anti-NG2 antibody. Tissues were rinsed in
PBS containing 0.3% triton X-100, and then incubated for 2 hour
at room temperature with secondary antibodies. Secondary
antibodies were goat anti-rat Alexa Fluor 555–conjugated
antibodies (1:500; Invitrogen) or goat anti-rabbit dylight 488–
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were rinsed in PBS containing 0.3% Triton X-100, and mounted
in anti-fade reagent.
Confocal scanning microscopy quantifications
Tissue sections were examined under a confocal microscope
(Olympus Confocal FV1000 Microscope). 2D images of each
tissue sample were assembled. Image acquisition was performed
maintaining the same laser power, gain, and offset settings.
Positive signals were photographed under a fluorescent micro-
scope (206objective magnification). In each mouse, 9–12 digital
fluorescence microscopic fields of view were analyzed randomly
and captured in a region measuring 5126512 mm. Images were
analyzed using ImageJ software. Endothelial cells (red channel:
CD31), basement membrane (green channel: type IV collagen),
and pericytes (green channel: NG2) of blood vessels in tumors were
quantified by measuring the proportion of sectional area (area
density). Based on an analysis of pixel fluorescence intensities,
which ranged from 0 to 255, specific staining was distinguished
from background by empirically using a threshold value of 40 or
50. Area densities of structures stained with CD31, type IV
collagen or NG2 were calculated as the proportion of pixels having
a fluorescence intensity value equal to or greater than the
corresponding threshold. We calculated the ratio of mean
fluorescence intensity of green to red channel. Values are
expressed as percentage of green to red co-staining.
Immunofluorescent visualization of tumor hypoxia
Hypoxia in tumors was detected by the formation of
pimonidazole adducts [9,11]. Pimonidazole hydrochloride com-
pound was injected intraperitoneally into each animal at a dose of
60 mg/kg. One hour after injection, mice were sacrificed, and
tumors were dissected and immediately fixed in either 4%
formalin or frozen. Frozen tumors were cut into 20 mm sections
which were then immunostained and used to detect pimonidazole
adducts by using Hypoxyprobe-1 Mab1 FITC Ab (Hypoxyprobe-
1 Plus kit; Chemicon) in the whole tumor regions (n=4–6 animals
per group) following the manufacturer’s instructions. The sample
counterstained with DAPI at 1 mg/mL. Images of the sections
were captured by using Olympus confocal FV1000 microscope at
2006 magnification. The slides were imaged using a computer
controlled scanning stage and later ‘‘stitched’’ together to gain one
image of the entire tumor. We calculated the ratio of green
(Pimonidazole) to blue (DAPI) channel mean fluorescence
intensity.
Immunohistochemistry for angiogenic factors
CNE-2 tumor-bearing mice were sacrificed 5 days after
endostar treatment. Tumor tissues from each group were
formalin-fixed and embedded in paraffin, then sectioned at
5 mm thickness and stained with H&E according to standard
immunohistochemical procedures. The sections were used to
detect the expression of vascular endothelial growth factor
(VEGF), pigment epithelium-derived factor (PEDF), matrix
metalloproteinase-2 (MMP-2), MMP-9, and MMP-14. The
samples were incubated with rabbit polyclonal VEGF (1:200;
Abcam), rabbit polyclonal PEDF (1:200; Chemicon), rabbit anti-
mouse polyclonal MMP-2 (1:50; Santa Cruz), rabbit polyclonal
MMP-9 (1:50; Labvision), rabbit polyclonal MMP-14 (1:50;
Thermo). Primary antibody diluent was used as a negative control
in all IHC studies. The immunoreactivity positive cells from each
of the differently treated tumor tissue sections were measured at
2006 magnification using a light microscope. The amount of
proteins was analyzed by integral optical density (IOD) using IPP
(Image Plus Pro 6.0, Bethesda, MD, USA).
Statistics
Means and SDs were calculated for continuous variables. For
two-group comparison, the t-test method was used. For more than
two groups’ comparison, one-way ANOVA was used firstly to
detect the differences amongst these groups. If the P-value was less
than 0.05, multiple comparison was performed using LSD-t test.
Statistical analyses of results were performed using the standard 2-
tailed Students t test by SPSS software version 13.0 (SPSS Inc.).
p,0.05 was considered statistically significant.
Results
Tumor vasculature
Immunofluorescent staining with antibody directed against
CD31 was used to investigate whether the tumor vascularization
and organization were modified after endostar treatment. Blood
vessels in untreated CNE-2 tumors were abundant, tortuous, and
variable in diameter (Fig. 1A-a), while tumor vessels that survived
after 9 days of treatment with endostar were less irregular, less
tortuous, more uniform in caliber, and had fewer branches and
sprouts (Fig. 1 A-b). Measurements of the vascularity of the tumors
showed a conspicuous reduction in CD31 immunoreactivity after
5, 7, or 9 days of treatment with endostar in CNE-2 xenografts
(Fig. 1B) and after 3, 5, or 7 days in 5–8F xenografts (Fig. 1C).
Overall vascularity decreased by 48% during 9 days of endostar
treatment in CNE-2 xenografts and 39% during 7 days of endostar
treatment in 5–8F xenografts.
Vascular basement membrane
Using CD31 and type IV collagen immunoreactivities as
markers, we compared the fates of endothelial cells and vascular
basement membrane of blood vessels during blood vessel
regression. Under baseline conditions, distinct strands of CD31
unaccompanied by type IV collagen staining indicated the absence
of basement membrane (Fig. 2A a–c). By comparison, the
conspicuous loss of CD31-positive vessels was not accompanied
by a corresponding reduction in type IV collagen after the
treatment with endostar. Capillaries had a continuous basement
membrane as reflected by type IV collagen and CD31
immunoreactivities (Fig. 2A d–f). The treatment with endostar
did significantly increase the percentage of basement membrane
sleeves in CNE-2 tumors (Fig. 2B), while a little increase was found
in 5–8F tumors (Fig. 2C). The percentages of type IV collagen
immunoreactivity in control and endostar-treated tumors after the
5 day treatment were 34.6% and 76.7% respectively.
Pericyte coverage
Increased pericyte coverage was considered as a key character-
istic of tumor vessel normalization. Accordingly, we analyzed the
pericyte coverage of tumor blood vessels after the treatment with
endostar. The expression of molecular markers that define specific
subpopulations of pericytes (NG2) was studied. We observed that
endostar substantially increased the pericyte coverage of tumor
blood vessels in CNE-2 xenografts after the treatment with
endostar for 5 days (Fig. 3A d–f), compared to the untreated
tumors (Fig. 3A a–c). After 5 days treatment with endostar, ratios
of NG2 immunoreactivity to CD31 immunoreactivity were
increased by 42% in CNE-2 xenografts and 56% in 5–8F
xenografts, respectively (Fig. 3B–C). Yet pericyte NG2 expression
returned to baseline by day 9 in CNE-2 xenografts and day 7 in 5–
8F xenografts after endostar treatments.
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To explore whether treatment with endostar resulted in an
increase in overall tumor oxygenation, we used pimonidazole
staining to evaluate the hypoxic fraction of both CNE-2 and 5–8F
xenografted tumors. Our findings demonstrated that the hypoxic
tumor fraction was significantly decreased on day 5 after the
treatment with endostar (Fig. 4A-b) compared with the saline-
treated mice in CNE-2 xenografts (Fig. 4A-a). During the
treatment of endostar, tumor hypoxia began to drop on day 1,
decreased by 59% on day 5, and increased again by day 9 in CNE-
2 xenografts (Fig. 4B). Similarly, it dropped on day 1, decreased by
38% on day 3, and increased again by day 9 in 5–8F xenografts
(Fig. 4C).
Tumor growth
We evaluated the effects of radiation and/or endostar on tumor
growth in vivo. Mice were randomly assigned to receive saline
treatment (control), radiation alone (6 Gy), endostar alone, or
radiation administered after 3, 5, 9 days treatment with endostar
in CNE-2 tumors and 3, 7 days treatment with endostar in 5–8F
tumors. We found that either endostar or radiation could modestly
inhibit tumor growth compared with untreated controls (Fig. 5,
p,0.05). In contrast, 5 days or 3 days after the treatment with
endostar administration of radiation significantly reduced the
CNE-2 or 5–8F tumor volumes compared with untreated control
mice or mice treated with radiation or endostar alone (Fig. 5,
p,0.05). When it was the maximum difference for the control,
endostar-treated, radiation-treated, and radiation after 3, 5, 9 days
treatment with endostar treated mice, tumor volumes in CNE-2
xenografts measured on day 17 were 17276151, 10676197,
8806176, 9826214, 473664, 9576197 mm
3, respectively. En-
dostar significantly enhanced the antitumor effect of radiation on
the day 5 in CNE-2 xenografts and the day 3 in 5–8F xenografts.
Animals treated with endostar (alone or in combination with
radiation) showed no signs of toxicity as assessed by unaltered
behavior, weight gain during experiments both in CNE-2 and 5–
8F xenografts.
Angiogenic factors
To further investigate whether vascular normalization was
associated with VEGF/PEDF balance and MMPs which were
involved in remodeling of the extracellular matrix, we used
immunostaining to assess the effects of endostar on the expression
of VEGF, PEDF, MMP-2, MMP-9 and MMP-14 in CNE-2
xenografted tissues. Our study suggested that VEGF were
decreased while PEDF were increased and concentrated in
CNE-2 tumor cells 5 days after endostar treatment. Meanwhile,
Figure 1. Regression of tumor vasculature after endostar treatment. CNE-2 and 5–8F tumors were removed and stained with anti-CD31
antibody. Tumor blood vessels were analyzed by confocal microscopy at different days after treatment as indicated. Tumor blood vessels are
presented in red. A-a: CD31 had an irregular distribution in control tumors after 9 days of treatment with vehicle in CNE-2 tumor. A-b: After the
treatment with endostar for 9 days, reduction in CD31 in CNE-2 tumor was reflected by decreased immunofluorescence. B–C: Quantification of CD31-
positive tumor vessels. Bar graphs illustrated changes in area density of CD31-positive vessels in CNE-2 and 5–8F tumors. Quantificatoin were
determined from 9–12 randomized cryosectioned fields (n=4–6 mice per group). Columns, means; bars, SEM. *p,0.05 compared with the control
group, * *p,0.01 compared with control (Student’s t-tests). Scale bar: 50 mm.
doi:10.1371/journal.pone.0034646.g001
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significantly decreased by endostar (Fig. 6).
Discussion
Preclinical and clinical studies have showed that anti-angiogenic
agents could normalize tumor vasculature. Winkler et al.
demonstrated that VEGFR-2 (VEGF receptor-2) blockade
DC101 reduced the mean basement membrane thickness while
the subcutaneously implanted mammary carcinomas had incom-
plete vascular basement membrane coverage [9]. Furthermore,
VEGFR-2 blockade DC101 has been reported to increase
basement membrane coverage to near normal levels. In addition,
many other anti-angiogenic agents, such as DC101, bevacizumab,
trastuzumab, erlotinib, TNP-470, gleevec, erbitux, sunitinib,
TSU68, and KRN951, can normalize the tumor vascular system
in a variety of animal models [9,11,16,28,29,30,31].
To explore whether endostar normalized the tumor vasculature
in NPC, we established the models of human CNE-2 and 5–8F
nasopharyngeal carcinoma xenografts in nude mice and treated
the mice with endostar as described in Materials and Methods.
Our observation showed that blood vessels in the endostar-treated
tumors were less irregular, less tortuous (Fig. 1). Furthermore, the
results indicated that the percentages of basement membrane and
pericyte coverage were significantly increased by endostar (Fig. 2–
3), which was thought to be a key property of vessel normalization
[32]. For all these reasons, our data demonstrated that endostar
Figure 2. Confocal microscopic images showing comparison of vascular basement membrane in NPC tumors with or without
endostar treatment. Fluorescence images of tumors showed CD31-positive endothelial cells (red), type IV collagen-positive basement membrane
(green), and merged images (orange). A: Some segments of CD31 lacked type IV collagen immunoreactivity in untreated CNE-2 tumors (a–c). Most
CD31 coincided with regions of type IV collagen-positive blood vessels 5 days after endostar treatment in CNE-2 tumors (d–f). B–C: Graphs of the
percentage of type IV collagen showed that basement membrane was increased during regression of endothelial cells in both CNE-2 and 5–8F
tumors. Quantification of type IV collagen-positive vessels versus total CD31-positive vessels were determined from 9–12 randomized cryosectioned
fields (n=4–6 mice per group). Columns, means; bars, SEM. *p,0.05 compared with the control group, * *p,0.01 compared with control (Student’s
t-tests). Scale bar: 50 mm.
doi:10.1371/journal.pone.0034646.g002
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day 7 after treatment in CNE-2 NPC xenografts and day 3 to day
5 after treatment in 5–8F NPC xenografts.
Vascular normalization alters intratumoral vascular physiology
by lowering interstitial fluid pressure, reducing vessel permeability,
and thus decreasing intratumoral hypoxia [13,33]. Consequently,
we further evaluated the effect of endostar on the hypoxic
condition of human NPC xenografts. Our data showed, in
agreement with the previous studies, that tumor hypoxic fraction
decreased on day 5 to day 7 in CNE-2 xenografts and day 3 to day
5 in 5–8F xenografts after endosar treatment (Fig. 4), which
suggested that intratumoral hypoxia was improved during the
endostar treatment.
Mounting evidence supports the view that alleviation of tumor
hypoxia and improved vascular delivery may enhance the
cytotoxic effects of chemotherapeutics and ionizing radiation [8].
Our data showed that the radiation response was the greatest
when radiation was administered on the day 5 in CNE-2
xenografts and day 3 in 5–8F xenografts after endostar treatment,
whereas the other time windows showed no benefits (Fig. 5), which
was consistent with the previous studies. Bevacizumab, an anti-
VEGFR antibody, has been demonstrated to induce tumor
vascular normalization and enhance the anti-tumor effects of
Figure 3. Confocal microscopic images showing comparison of pericyte coverage in NPC tumors with or without endostar
treatment. Fluorescence images of tumors showed CD31-positive endothelial cells (red), NG2-positive pericytes (green), and merged images
(orange). A: Some segments of CD31 lacked NG2 immunoreactivity in untreated CNE-2 tumors (a–c). The intensity of NG2 immunofluorescence
colocalized with CD31 staining were increased 5 days after endostar treatment in CNE-2 tumors (d–f). B–C: Graphs of the percentage of NG2 showed
that pericytes were increased during regression of endothelial cells in both CNE-2 and 5–8F tumors. Quantification of percentages of NG2-positive
vessels versus total CD31-positive vessels was determined from 9–12 randomized cryosectioned fields (n=4–6 mice per group). Columns, means;
bars, SEM. *p,0.05 compared with the control group, * *p,0.01 compared with control (Student’s t-tests). Scale bar: 50 mm.
doi:10.1371/journal.pone.0034646.g003
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reported that radiation therapy delivery was most effective during
a ‘‘tumor oxygenation window’’ after treatment with bevacizumab
in heterotopic models of human ovarian carcinoma, murine
melanoma, and breast carcinoma [11]. Meanwhile, bevacizumab
has been demonstrated to improve intratumoral oxygenation and
enhance the antitumor activity of ionizing radiation in glioma
[13]. Preliminary results of a phase II clinical study of
chemoradiation plus bevacizumab for locally/regionally advanced
NPC (RTOG 0615) suggested that bevacizumab prolonged overall
survival [34]. Therefore, the results of the present study are of
translational importance for not only clarified that endostar could
create a vascular normalization time window after treatment in
NPC xenografts, but aslo showed that the anti-tumor effect of
irradiation was enhanced during the normalization time induced
by delivering endostar.
Interestingly, the combination of radiation with endostar
showed enhanced anti-tumor effects, which can be attributed to
the local decrease in tumor hypoxia and the increase in
oxygenation. However, at day 3 and day 9 the addition of
endostar lacks even an additive benefit to radiation therapy in
CNE-2 xenografts. One possibility was the transient nature of
vascular normalization after endostar treatment, which was likely
due to expression of alternative pro-angiogenic factors by tumors
[35]. However, the underlying mechanisms need to be further
investigated.
Malignant tissues produce multiple angiogenic factors to induce
neovascularization, which significantly contributes to tumor
growth and metastasis. Of all the known angiogenic molecules,
VEGF (vascular endothelium growth factor) appears to be the
most critical. VEGF promotes the survival and proliferation of
endothelial cells and increases vascular permeability [36]. VEGF is
overexpressed in the majority of solid tumors and down-regulating
VEGF signaling might normalize tumor vasculature [32]. Some
studies provide evidence that severe abnormalities of the vascular
basement membrane in tumor vessels are mediated by VEGF
signaling, since VEGFR-2 blockade restores a thinner, more
closely attached basement membrane monolayer [9]. Pigment
Figure 4. Confocal microscopic images showing comparison of tumor hypoxia in NPC tumors with or without endostar treatment.
Tumor hypoxia (pimonidazole staining, green) was severe in control tumors (A-a), but decreased on day 5 during monotherapy with endostar (A-b) in
CNE-2 tumor. Hypoxia reached a minimum at day 5, and a partial relapse occurred at day 9 in CNE-2 tumor (B), while hypoxia reached a minimum at
day 3, and a relapse occurred at day 7 in 5–8F tumor (C). Quantification of hypoxic tumor fraction was determined from the whole tumor
cryosectioned fields (n=4–6 mice per group). Columns, means; bars, SEM. *p,0.05 compared with the control group, * *p,0.01 compared with
control (Student’s t-tests). Scale bar: 1 mm.
doi:10.1371/journal.pone.0034646.g004
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and anti-tumor factor [37], is more potent than any other known
endogenous inhibitors of angiogenesis, being more than twice as
potent as angiostatin and seven times more potent than endostatin
[38]. Furthermore, VEGF/PEDF ratio is a key molecular
mechanism for antiangiogenic therapy against malignant diseases.
Gao et al. reported that plasminogen kringle 5 could down-
regulate VEGF and up-regulate PEDF thus to decrease the
VEGF/PEDF ratio, and lead to the restoration of a normal
balance between angiogenic stimulators and inhibitors, which
might be the mechanism for the anti-angiogenic activity of
plasminogen kringle 5 [39]. In the present study, we found that
VEGF was down-regulated by endostar, while PEDF was up-
regulated (Fig. 6). We speculated that during the normalization
window, endostar increased pericyte coverage of NPC tumor
Figure 5. Effect of the combination of endostar and radiation on NPC tumor growth. Subcutaneously implanted CNE-2 and 5–8F
xenografted tumors were established as described in Materials and Methods. When xenografted tumors reached a volume of 100 mm
3, mice in CNE-
2 xenografts were randomly divided into six groups (n=6–8 per group): con, control (0.9% saline); endo, endostar only; R, radiation at a single dose of
6 Gy only; endo+R3, radiation at a single dose of 6 Gy on the 3
rd day after endostar treatment; endo+R5, radiation at a single dose of 6 Gy on the 5
th
day after endostar treatment; endo+R9, radiation at a single dose of 6 Gy on the 9
th day after endostar treatment. Mice in 5–8F xenografts were
randomly divided into five groups (n=6–8 per group): con, control; endo, endostar only; R, radiation at a single dose of 6 Gy only; endo+R3, radiation
at a single dose of 6 Gy on the 3
rd day after endostar treatment; endo+R7, radiation at a single dose of 6 Gy on the 7
th day after endostar treatment.
Endostar was administered at a dose of 20 mg/kg/d for 10 days from the first day of treatment. A, C: The growth curve of CNE-2 and 5–8F tumor
xenografts. Radiation induced a significantly tumor suppression when combining with endostar on day 5 and day 3. B, D: A combination of radiation
and endostar is synergistic only during a ‘‘normalization window’’ when tumor hypoxia is greatly diminished. Each point represents the mean tumor
size. Columns, means; bars, SEM. *p,0.05 compared with the control group, * *p,0.01 compared with control (ANOVA, LSD-t test).
doi:10.1371/journal.pone.0034646.g005
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thus inhibiting VEGF singaling.
MMPs, a family of extracellular and membrane-associated
endopeptidases, collectively digest almost all extracellular matrix
and basement membrane components. They play a crucial role in
various physiological processes including tissue remodeling and
organ development and thus in tumor progression [40]. Recent
studies have identified MMPs as modulators of the tumor
microenvironment [41]. MMP-2, MMP-9, and MMP-14 have
been reported to be involved in tumor angiogenesis and
extracellular matrix remodeling. Our study provided evidence
that endostar decreased MMP-2, MMP-9, and MMP-14 expres-
sion, which could be responsible for reduced angiogenesis in
treated CNE-2 NPC xenografts compared to controls (Fig. 6). This
suggestion is supported by previous studies in which showed the
involvement of these MMPs in tumor angiogenesis [42,43].
However, the effects of MMPs on tumor vascular normalization
remain unknown and further investigation is required. We
presumed that the downregulation of MMP-2, MMP-9 and
MMP-14 might alleviate the extracellular matrix (ECM) degra-
dation, thus maintaining the vascular basement membrane and
normalizing tumor vasculature.
In general, we concluded that endostar normalized tumor
vasculature within a time window, alleviated hypoxia and
significantly sensitized the antitumor effect of radiation in NPC
xenograft models. We found that during the normalization
window, endostar might increase pericyte coverage of NPC tumor
vessels via upregulation of PEDF and downregulation of VEGF,
thus inhibiting VEGF singaling. Our data implies that endostar
might be a potent adjuvant therapeutic agent for NPC therapy in
combination with radiotherapy. These results are of translational
importance because the clinical benefits of endostar therapy might
be increased by more precise treatment scheduling to ensure that
radiation is given during periods of peak radiosensitivity.
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